Sea Change for Marine Omega-3s: Randomized Trials Show Fish Oil Reduces Cardiovascular Events

Recently, 3 large randomized controlled trials (RCTs) have assessed the effects of supplementation with marine omega-3 fatty acids on the occurrence of cardiovascular disease (CVD) events. We reviewed this evidence and considered it in the context of the large and growing body of data on the CV heal...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Mayo Clinic proceedings 2019-12, Vol.94 (12), p.2524-2533
Hauptverfasser:	O'Keefe, Evan L, Harris, William S, DiNicolantonio, James J, Elagizi, Andrew, Milani, Richard V, Lavie, Carl J, O'Keefe, James H
Format:	Artikel
Sprache:	eng
Schlagworte:	Angina pectoris Cardiac patients Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - prevention & control Clinical trials Coronary heart disease Diabetes Disease prevention Evolocumab Fatty acids Fish oils Fish Oils - therapeutic use Health Health aspects Health risk assessment Heart diseases Humans Icosapent ethyl Mineral oils Omega 3 fatty acids Randomized Controlled Trials as Topic Seafood Statins Stroke Triglycerides Unsaturated fatty acids Vitamin B
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recently, 3 large randomized controlled trials (RCTs) have assessed the effects of supplementation with marine omega-3 fatty acids on the occurrence of cardiovascular disease (CVD) events. We reviewed this evidence and considered it in the context of the large and growing body of data on the CV health effects of marine omega-3s. One RCT examining 8179 patients, most with coronary heart disease (CHD), reported that 4 grams/day of a highly purified omega-3 product containing eicosapentaenoic acid (EPA) reduced the risk for major adverse CV events by 25% (P
ISSN:	0025-6196 1942-5546
DOI:	10.1016/j.mayocp.2019.04.027